UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(mark one)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2003
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER: 000-33477
GENESIS MICROCHIP INC.
(Exact name of registrant as specified in its charter)
| DELAWARE | 77-0584301 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| 2150 GOLD STREET P.O. BOX 2150 ALVISO, CALIFORNIA |
95002 | |
| (Address of principal executive offices) | (Zip Code) |
REGISTRANTS TELEPHONE NUMBER, INCLUDING AREA CODE: (408) 262-6599
Former name, former address and former fiscal year if
changed since last report.
Former address: N/A
Former Fiscal Year: N/A
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act):
Yes x No ¨
There were 32,086,555 shares of the registrants common shares issued and outstanding as of December 31, 2003.
FORM 10-Q
THREE MONTHS ENDED DECEMBER 31, 2003
| Item Number |
Page | |
| Part I: Financial Information |
||
| Item 1. Financial Statements |
||
| Condensed Consolidated Balance Sheets at December 31, 2003 and March 31, 2003 |
1 | |
| 2 | ||
| 3 | ||
| 4 | ||
| Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations |
10 | |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk |
26 | |
| Item 4. Controls and Procedures |
26 | |
| Part II: Other Information |
||
| Item 1. Legal Proceedings |
27 | |
| Item 2. Changes in Securities |
* | |
| Item 3. Defaults Upon Senior Securities |
* | |
| 29 | ||
| Item 5. Other Information |
29 | |
| Item 6. Exhibits and Reports on Form 8-K |
29 | |
| 30 | ||
| * | No information has been provided because this item is not applicable. |
| ITEM 1: | FINANCIAL STATEMENTS |
GENESIS MICROCHIP INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except per share amounts)
| December 31, 2003 |
March 31, 2003 |
|||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 55,850 | $ | 113,138 | ||||
| Short-term investments |
68,477 | | ||||||
| Accounts receivable trade, net of allowance for doubtful accounts of $489 at December 31 and $493 at March 31 |
26,208 | 25,587 | ||||||
| Inventories |
26,779 | 14,269 | ||||||
| Other |
6,019 | 5,697 | ||||||
| Total current assets |
183,333 | 158,691 | ||||||
| Property and equipment |
16,277 | 12,770 | ||||||
| Acquired intangibles |
29,232 | 36,933 | ||||||
| Goodwill |
189,579 | 189,579 | ||||||
| Deferred income taxes |
2,113 | | ||||||
| Other |
2,148 | 4,681 | ||||||
| Total assets |
$ | 422,682 | $ | 402,654 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 24,481 | $ | 8,640 | ||||
| Accrued liabilities |
12,485 | 18,164 | ||||||
| Income taxes payable |
2,475 | 722 | ||||||
| Loans payable |
335 | 334 | ||||||
| Total current liabilities |
39,776 | 27,860 | ||||||
| Long-term liabilities: |
||||||||
| Deferred income taxes |
| 961 | ||||||
| Total liabilities |
39,776 | 28,821 | ||||||
| Stockholders equity: |
||||||||
| Capital Stock: |
||||||||
| Preferred stock: |
||||||||
| Authorized - 5,000 preferred shares, $0.001 par value Issued and outstanding - none at December 31 or March 31 |
||||||||
| Common Stock: |
||||||||
| Authorized - 100,000 common shares, $0.001 par value Issued and outstanding - 32,087 shares at December 31 and 31,184 shares at March 31 |
32 | 31 | ||||||
| Additional paid-in capital |
390,914 | 382,587 | ||||||
| Cumulative other comprehensive loss |
(94 | ) | (94 | ) | ||||
| Deferred stock-based compensation |
(3,798 | ) | (6,809 | ) | ||||
| Deficit |
(4,148 | ) | (1,882 | ) | ||||
| Total stockholders equity |
382,906 | 373,833 | ||||||
| Total liabilities and stockholders equity |
$ | 422,682 | $ | 402,654 | ||||
See accompanying notes to condensed consolidated financial statements.
1
GENESIS MICROCHIP INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except per share amounts)
(unaudited)
| Three Months Ended December 31 |
Nine Months Ended December 31 |
|||||||||||||||
| 2003 |
2002 |
2003 |
2002 |
|||||||||||||
| Revenues |
$ | 56,498 | $ | 51,682 | $ | 158,548 | $ | 139,545 | ||||||||
| Cost of revenues (1) |
34,146 | 32,623 | 94,013 | 88,283 | ||||||||||||
| Gross profit |
22,352 | 19,059 | 64,535 | 51,262 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Research and development (2) |
7,417 | 8,001 | 22,522 | 26,024 | ||||||||||||
| Selling, general and administrative (3) |
9,515 | 8,942 | 28,826 | 26,752 | ||||||||||||
| Amortization of acquired intangibles |
2,654 | 2,654 | 7,962 | 7,973 | ||||||||||||
| Costs associated with patent litigation |
3,529 | 10,163 | 9,583 | 11,561 | ||||||||||||
| Total operating expenses |
23,115 | 29,760 | 68,893 | 72,310 | ||||||||||||
| Loss from operations |
(763 | ) | (10,701 | ) | (4,358 | ) | (21,048 | ) | ||||||||
| Interest income |
314 | 590 | 786 | 1,422 | ||||||||||||
| Gain on sale of investment |
663 | | 663 | | ||||||||||||
| Imputed interest on lease liability |
| (160 | ) | | (490 | ) | ||||||||||
| Net interest and other income |
977 | 430 | 1,449 | 932 | ||||||||||||
| Income (loss) before income taxes |
214 | (10,271 | ) | (2,909 | ) | (20,116 | ) | |||||||||
| Provision for (recovery of) income taxes |
35 | (3,244 | ) | (643 | ) | (4,461 | ) | |||||||||
| Net income (loss) |
$ | 179 | $ | (7,027 | ) | $ | (2,266 | ) | $ | (15,655 | ) | |||||
| Earnings (loss) per share: |
||||||||||||||||
| Basic |
$ | 0.01 | $ | (0.22 | ) | $ | (0.07 | ) | $ | (0.50 | ) | |||||
| Diluted |
$ | 0.01 | $ | (0.22 | ) | $ | (0.07 | ) | $ | (0.50 | ) | |||||
| Weighted average number of common shares outstanding: |
||||||||||||||||
| Basic |
31,948 | 31,306 | 31,655 | 31,445 | ||||||||||||
| Diluted |
33,201 | 31,306 | 31,655 | 31,445 | ||||||||||||
| (1) Amount excludes amortization of acquired developed technology included in amortization of acquired intangibles of: |
$ | 1,925 | $ | 1,925 | $ | 5,775 | $ | 5,775 | ||||||||
| (2) Amount includes non-cash stock-based compensation of: |
$ | 723 | $ | 1,631 | $ | 2,162 | $ | 4,631 | ||||||||
| (3) Amount includes non-cash stock-based compensation of: |
$ | 207 | $ | 270 | $ | 608 | $ | 1,212 | ||||||||
See accompanying notes to condensed consolidated financial statements.
2
GENESIS MICROCHIP INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
(unaudited)
| Nine Months Ended |
||||||||
| December 31, 2003 |
December 31, 2002 |
|||||||
| Cash flows from operating activities: |
||||||||
| Net loss |
$ | (2,266 | ) | $ | (15,655 | ) | ||
| Adjustments to reconcile net loss to cash from operating activities: |
||||||||
| Depreciation and amortization |
3,569 | 4,122 | ||||||
| Amortization of acquired intangibles |
7,962 | 7,973 | ||||||
| Non-cash stock-based compensation |
2,770 | 5,843 | ||||||
| Deferred income taxes |
(3,074 | ) | (4,870 | ) | ||||
| Gain on sale of investment |
(663 | ) | | |||||
| Other |
(1 | ) | 519 | |||||
| Change in operating assets and liabilities: |
||||||||
| Accounts receivable trade |
(621 | ) | 7,836 | |||||
| Inventories |
(12,510 | ) | 2,425 | |||||
| Other current assets |
(322 | ) | (627 | ) | ||||
| Accounts payable |
15,841 | 2,507 | ||||||
| Accrued liabilities |
(5,679 | ) | 2,340 | |||||
| Income taxes payable |
1,753 | 359 | ||||||
| Net cash from operating activities |
6,759 | 12,772 | ||||||
| Cash flows used in investing activities: |
||||||||
| Purchase of short-term investments |
(68,477 | ) | (3,034 | ) | ||||
| Proceeds on sales and maturities of short-term investments |
| 7,836 | ||||||
| Additions to property and equipment |
(6,991 | ) | (5,657 | ) | ||||
| Other |
2,852 | (1,413 | ) | |||||
| Net cash used in investing activities |
(72,616 | ) | (2,268 | ) | ||||
| Cash flows provided by financing activities: |
||||||||
| Proceeds from issue of common stock |
8,569 | 4,245 | ||||||
| Repurchase of common stock |
| (3,127 | ) | |||||
| Repayment of loans payable |
| (90 | ) | |||||
| Net cash provided by financing activities |
8,569 | 1,028 | ||||||
| Increase (decrease) in cash and cash equivalents |
(57,288 | ) | 11,532 | |||||
| Cash and cash equivalents, beginning of period |
113,138 | 106,564 | ||||||
| Cash and cash equivalents, end of period |
$ | 55,850 | $ | 118,096 | ||||
| < | ||||||||